30 closest matches · ranked by relevance
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Von Hippel-Lindau Syndrome
Primary: Overall Response Rate (Complete Response + Partial Response) — 13 Participants
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
VHL Gene Mutation · VHL · VHL Syndrome
Primary: Overall Response Rate (ORR) in VHL Disease-Associated ccRCC Tumors — 0.0 Percentage of Participants
Renal Cancer · Von Hippel Lindau
Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants
Von-Hippel Lindau · Kidney Disease, Chronic
Primary: Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound — 0.13; 0.20 Dichotomized score
HLRCC · Sporadic Papillary Renal Cell Cancer
Primary: Overall Response Rate — 72; 35 Percentage of participants
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Leber Congenital Amaurosis
Primary: Overall Safety of Adeno-Associated Virus Vector (AAV-OPTIRPE65) - Number of Participants With a Safety Event — 0; 0; 1; 0 Participants
Melanoma · Skin Cancer
Primary: Overall Response to CVT Chemotherapy. — 1; 5 participants
Metastatic Cancers
Primary: Percentage of Participants With V600 BRAF Mutation Status — 41.3; 58.3; 0.4 percentage of participants
Renal Cell Carcinoma
Primary: Progression-free Survival — 1.7 months
Lung Cancer
Primary: Progression Free Survival — 16; 10.5 months
TSC1 · TSC2 · Tuberous Sclerosis Complex
Primary: Objective Response Rate — 2 Participants
Choroideremia · CHM (Choroideremia) Gene Mutations
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 5; 5; 5 Participants
Multiple Myeloma, Neoplasms
Primary: Percentage of Participants With BRAF V600 Mutation Positivity in Tumor Samples by Cancer Type — 0; 3; 11; 0 percentage of participants
Choroideremia
Primary: Change in Best Corrected Visual Acuity From Baseline — 3.0 Letters
Lung Cancer
Primary: Clinically Significant Event (CSE) — 0.425 Proportion of subjects — p=< .0001
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Hepatocellular Carcinoma
Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale
Solid Tumors
Primary: Time From Patient Recruitment to Final Results ≤ 21 Days in ≥ 90% of Patients — 21 calendar days
Retinoschisis · X-Linked
Primary: Adverse Events (AEs) Affecting Ocular Function That Differ Clinically From Those Expected in the Normal Course of Progression of XLRS — 3; 3; 12; 6 events
Vestibular Schwannoma · NF2 · Neurofibromatosis 2
Primary: Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection — 3149 ng/mL
Cystic Fibrosis
Primary: Part A: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging (3He-MRI) at Day 43 — -8.20 percentage of total…
Gastric Cancer · Gastric Neoplasms · Gastric Adenocarcinoma
Primary: Proportion of Participants With Improved Sensitivity for Detection of Early-stage Gastric Cancer in CDH1 Germline Mutation Carriers Compared to the Cambridge Method — 1…
Congenital Heart Disease
Primary: To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665 — 10 participants
Actinic Keratosis
Primary: Percent Change From Baseline in Lesion Count at Week 18 — 95.5 percent change
Neurofibromatosis Type 2 · Progressive Vestibular Schwannomas
Primary: Improvement in Hearing — 9 Participants